Actively Recruiting
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Led by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. · Updated on 2025-12-03
50
Participants Needed
4
Research Sites
191 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed/refractory B-cell malignancies.
CONDITIONS
Official Title
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older at the time of signing informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Histologically confirmed diagnosis of relapsed or refractory B-cell malignancy including chronic lymphocytic leukemia (CLL), Richter's transformation from CLL, mantle-cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, or marginal zone lymphoma
- Participants have relapsed after standard care, progressed during standard care, or are unsuitable for standard care therapy
You will not qualify if you...
- Any medical or psychiatric condition that could compromise safety or participation as judged by the Principal Investigator
- Known central nervous system malignancy or primary CNS lymphoma
- Concurrent active or previous malignancy other than the primary lymphoma/CLL within 5 years prior to randomization, except with documented Sponsor approval
- Received anticancer therapy including chemotherapy, immunotherapy, radiation (except palliative), biologic therapy, hormonal therapy, or investigational therapy within 21 days or 5 half-lives before the first study dose
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Hospital Fundación Jiménez Diaz
Madrid, Spain
Actively Recruiting
2
Hospital Universitario HM Sanchinarro
Madrid, Spain
Actively Recruiting
3
St James's University Hospital
Leeds, United Kingdom
Actively Recruiting
4
University Hospitals Plymouth NHS Trust
Plymouth, United Kingdom
Actively Recruiting
Research Team
E
Exscientia AI Ltd.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here